

**MOSA02 ONE SADC, ONE VISION, ONE WAY: WALKING THE TALK**

Non-Commercial Satellite

**Venue:** Room 103

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC)

The SADC region is the epicenter of the global HIV epidemic. HIV is a major threat to the social and health well-being of communities in the region and economic development of the 15 Member States. To respond to this challenge, the SADC Heads of States and Governments signed the HIV Declaration, called the Maseru Declaration in 2003, which among others set up an HIV Trust Fund to finance innovative initiatives to be implemented through collaborative arrangements by a minimum of 3 countries. To date, 10 projects which have been financed by the HIV and AIDS Fund have been completed. The projects have, among things, increased capacity of to address HIV prevention scaled up PMTCT and addressed access issues for key populations in SADC Member States. The knowledge generated from the projects will inform the region in developing evidence based policies/interventions and future strategies in the post 2015.

**Keynote Speaker: Decisive leadership in providing concrete policy guidance for an effective and home grown response and mainstreaming of HIV, Gender and Human rights in all sectors and in the communities**

*T.Bisika, Malawi*

**From policy to practice: SADC Member States making a difference.**

*D.Magure, Zimbabwe*

**Tangible results from domestically financed projects: Remembering young people, the future of tomorrow**

**- 'Needs, Challenges and Opportunities for Adolescents living with HIV in Southern Africa'**

*D.Cataldo, Malawi*

**Tangible results from domestically financed projects: Reaching communities - 'Communicating HIV prevention: Empowering local communities to drive the HIV response in the SADC Region'**

*M.Chingona, Zambia*

**Working in unison: Together for greater impact .**

*M.Mangani, Zambia*

**MOSA03 By women for women. Harm reduction among women who inject drugs**

Non-Commercial Satellite

**Venue:** Room 203-204

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** United Nations Office on Drugs and Crime (UNODC) and International Network of Women who Use Drugs (INWUD)

Women who inject drugs are particularly affected by HIV, yet few HIV services tailored to their needs.

This session will showcase experiences and lessons learned in working with this population and show the value and importance of tailoring services to women's needs and involving them in the design and implementation stages. The session will stimulate a discussion on good practices in the field of HIV comprehensive service provision for women who use drugs, as well as raise awareness among attendees on the importance scaling up of these life-saving services.

At the session, UNODC will also launch two publications providing up-to-date information on HIV prevention, treatment and care related to women who use drugs. (1) Policy Paper to Address Specific Harm reduction Needs of Women Who Use Drugs and (2) Practical Guide on Interventions Addressing the Needs of Women Who Use Drugs. Both publications were developed with INWUD, WHRIN and EHRN.

**Introduction by Chair**

**Drug Policy and Women: Addressing the Negative Consequences of Punitive Practices**

*R.Birgin, Australia*

**Women and Harm Reduction**

*T.Azim, Bangladesh*

**Gender Responsive Services for Women Who Use Drugs in Indonesia**

*E.Vinanti Nugraheni, Indonesia*

**Providing Safe Environments to Women who Inject Drugs**

*M.Demchenko, Ukraine*

**Addressing the Specific Needs of Women who Inject Drugs - UNODC Policy Paper and Practical Guide**

*M.Beg, UNODC*

**Discussion**

**MOSA04 The Impact of HIV Funding on Trans\* Communities: Keeping Human Rights Central to the HIV Response**

Non-Commercial Satellite

**Venue:** Room 101-102

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** American Jewish World Service (AJWS); amfAR, The Foundation for AIDS Research; Global Action for Trans\* Equality (GATE)

The goal of the session is to generate a dialogue about the following issues: a) the impact of HIV on trans\* communities and why HIV response needs to be driven by a human rights-based approach b) local activism by trans\* groups focused on human rights issues and the impact of HIV on their work and c) key findings from The State of Trans\* and Intersex Organizing funding report and important recommendations for how HIV-focused organizations and LGBTIQ organizers can increase support for trans\* and intersex activists and organizing efforts. Speakers include: Joe Wong, Asia Pacific Trans Network (APTN); LeighAnn van der Merwe, Social Health and Empowerment Feminist Collective of Transgender and Intersex Women of Africa (S.H.E.); Nicha Chaiyapreuk, Thai Transgender Alliance (Thai-TGA); Justus Eisfeld, Global Action for Trans\* Equality (GATE). The panel will be moderated by activist Jack Byrne.

**The Impact of HIV Funding on Trans\* Communities: Keeping Human Rights Central to the HIV Response**

*J.Eisfeld, United States; J.Wong, Thailand; L.van der Merwe, South Africa; N.Rongram, Thailand*

**MOSA06 Innovations in HIV treatment delivery Towards the virtual elimination of AIDS**

Non-Commercial Satellite

**Venue:** Room 105-106

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** UNAIDS

Antiretroviral therapy has been recognized as the central tool to prevent HIV-related illness and death and a key element of an effective combination of prevention strategies. Although the world now has the tools to virtually end AIDS, the transformative potential of antiretroviral therapy has yet to be fully realized, in part due to shortcomings of testing and treatment programmes. Only 34% of people eligible for HIV treatment under the 2013 WHO consolidated antiretroviral guidelines were receiving antiretroviral therapy as of December 2012, and many people who initiate HIV treatment do not achieve durable viral suppression. This satellite session will provide technical back-up to Sunday's high-level political session 'A New Target for HIV Treatment Scale-up: Ending the AIDS epidemic' (15:45-17:45) and will focus on the key evidence-based programmatic actions needed to rapidly scale up treatment to achieve the post 2015 HIV treatment targets.

**Deputy Executive Director, UNAIDS**

*M.Doherty, WHO*

**Director, British Columbia Center of Excellence in HIV/AIDS**

*J.Montaner, Canada*

**Deputy Director-General, National Department of Health, South Africa**

*Y.Pillay, South Africa*

**President and CEO, Elizabeth Glaser Pediatric AIDS Foundation**

*C.Lyons, United States*

**Professor and Chair of Diagnostics Research, London School of Hygiene and Tropical Medicine.**

*R.Peeling, United States*

**Deputy Assistant Minister for International Affairs, Japan**

*Y.Horrie, Japan*

**Medical Coordinator, Médecins Sans Frontières**

*D.Belén Garone, Switzerland*

**MOSA07 HIV in Papua New Guinea: Leveraging Public-Private Partnerships**

Non-Commercial Satellite

**Venue:** Room 109-110

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** Oil Search

This satellite explores how public-private partnerships are leveraged in the response to HIV in Papua New Guinea (PNG), highlighting in particular the role of the private sector in building innovative partnerships that form the foundation for successful public health interventions.

Papua New Guinea is a very challenging environment to operate; especially to implement and scale-up HIV interventions in rural and remote regions. In many of these difficult to reach regions the private sector, and in particular the resource industry, has a strong operational and logistical capacity that can be leveraged to strengthen health systems.

One significant public-private partnership in PNG is between resource sector operator Oil Search, the National Department of Health, and the Global Fund to Fight AIDS, Tuberculosis and Malaria. This partnership under the Global Fund Round 10 HIV grant brings together corporate business systems, technical country expertise, and multilateral funding to step up the pace in PNG.

**Welcome and introductions**

*J.Chau, UNAIDS Goodwill Ambassador, China*

**Papua New Guinea's HIV response**

*P.O'Neill, Prime Minister of Papua New Guinea (In principle), Papua New Guinea*

**VIDEO: Living with HIV in Papua New Guinea**

**The New Aid Paradigm and private sector's role**

*J.Bishop, Foreign Minister, Australia (TBC), Australia*

**The role of the private sector in the HIV response in PNG**

*P.Botten, Managing Director, Oil Search, Australia*

**Stepping up the pace in PNG**

*S.Lewin, Local Co-Chair, AIDS 2014, Australia*

**The Global Fund and public-private partnerships**

*M.Dybul Executive Director Global Fund, United States*

**The future of PPPs in the response to HIV**

*J.Beagle, Deputy Executive Director, UNAIDS, New Zealand*

**MOSA08 Taking stock – opportunities, challenges, visions: Where next with the PLHIV Global Advocacy Agenda?**

Non-Commercial Satellite

**Venue:** Room 111-112

**Date:** Monday 21 July

**Time:** 07:00-08:30

**Organizer:** Global Network of People Living with HIV (GNP+) in partnership with others.

This is an interactive breakfast session over coffee and croissants to assess the successes, challenges and next steps for the PLHIV Global Advocacy Agenda 2013-2015. The session will include many of the partners involved, highlighting what has been done, giving examples of progress made and where progress has been blocked. This will be followed by a moderated panel discussion and Q&A session. The session will address strands from within the three areas of the Global Advocacy Agenda:

- Prevention, Treatment, Care and Support
  - Human Rights
  - Community Mobilisation, strengthening and activism
- What are the areas in the GAA that the communities of PLHIV and their allies have made the most/least progress against and why?

What are the new opportunities and threats that can undermine the implementation of the GAA?  
How can the PLHIV GAA contribute to a better development, implementation and monitoring of the Post 2015 Development agenda?

**Opening and welcome to session from Suzette Moses-Burton, background on the PLHIV Global Advocacy Agenda**

*S.Moses-Burton, Netherlands*

**Treatment literacy, diagnostics and monitoring, care and support for PLHIV - A view from Sushil Koirala, Programme Manager of APN+**

*S.Koirala, Thailand*

**Increasing access to ARV drugs for all those who need them - A view from Sylvere Bukiki - Regional Coordinator of ITPC West Africa**

*S.Bukiki, Cote D'Ivoire*

**Criminalization of HIV - the challenges and the successes. Views from from Edwin Bernard (HIV Justice Network) and Dora Kinconco (UGANET) including news from 'Beyond Blame' - the criminalisation pre-conference**

*E.Bernard, United Kingdom; D.Kinconco, Uganda*

**Funding for the HIV response - a view from Rachel Ong, Communications Focal Point for the Communities delegation to the GFATM**

*R.Ong, Singapore*

**Engagement of key populations, including YPLHIV in networks of PLHIV - views from Representatives from the Key Populations network (TBC) and Musah Lumumba (Y+)**

*M.Lumumba, Uganda; C.Chung TBC, United States*

**Moderated Panel discussion with Q and A from participants:**  
**New opportunities and additional challenges to the implementation of the Global Advocacy Agenda**  
 This will be moderated and facilitated by Laurel Sprague.

**Panellists:**  
**All presenters plus Olga Aleksandrova (ECUO) and other guests. We welcome an active discussion of the issues from ALL present.**

*O.Aleksandrova, Ukraine; L.Sprague, United States*

**Final reflections and closure:**

**Suzette Moses-Burton**

*S.Moses-Burton, Netherlands*

**WESA04 Changing the Course of the Epidemic: Using Data, Modeling, Economic Analyses, and Innovation to Improve Program Impact**

Non-Commercial Satellite

**Venue: Room 104**

**Date: Monday 21 July**

**Time: 07:00-08:30**

**Organizer: U.S. President's Emergency Plan for AIDS Relief (PEPFAR)**

The session will focus on PEPFAR efforts to maximize data use and analysis in order to significantly increase the impact per dollar of PEPFAR programs. The session will highlight how triangulated data (epidemiologic, modeling, cost and quality data) has been used to scale-up, and scale-out, HIV/AIDS programs at the national and local level.

**U.S. Global AIDS Coordinator**

*D.Birx, United States*

**PEPFAR Ethiopia**

*J.Felter Brown, United States*

**ART Program Representative**

*W.El-Sadr, United States*

**PMTCT Program Representative**

*Z.Namukwaya, Uganda*

**VMMC Program Representative**

*K.Curran, United States*

**MAT Program Representative**

*P.Smyrnov, Ukraine; A.Klepikov, Ukraine*

**Audience Q/A**

**MOSA01 Bone and Renal Comorbidities in HIV: The Osteo-Renal Exchange Program**

Major Industry Sponsor Satellite

**Venue: Melbourne Room 1**

**Date: Monday 21 July**

**Time: 18:30-20:30**

**Organizer: AbbVie**

TBD

**Introduction**

*B.Powderly, United States*

**Bone and Renal Disease in HIV**

*B.Powderly, United States*

**Bone Recommendations**

*J.Hoy, Australia*

**Renal Recommendations**

*M.Atta, United States*

**Panel Discussion**

*C.Knud Schewe, Germany; B.Powderly, United States; J.Hoy, Australia; M.Atta, United States*

**MOSA05 Women, HIV/AIDS and Non-Communicable Diseases: A Call to Action in Lower and Middle Income Countries**

Non-Commercial Satellite

**Venue: Plenary 3**

**Date: Monday 21 July**

**Time: 18:30-20:30**

**Organizer: Management Sciences for Health (MSH), American Cancer Society, co-conveners for Task force on Women and NCDs**

This session will inform & engage the HIV/AIDS community in the prevention and treatment of non-communicable diseases (NCDs) in HIV-infected women. To ensure that women living with HIV have their full health needs met, we must understand the links between HIV and cancer, diabetes, heart disease and chronic respiratory illnesses. The double burden of HIV and NCD among women residing in low and middle income countries will increase substantially in the coming decades, particularly in Africa. Our goal is to examine what we know about addressing HIV-comorbidities in both AIDS and Non-AIDS related events; the role of health systems in integrating NCD care into HIV care models; determine which lessons could be leveraged beyond 2015 in the context of an emerging global burden of chronic NCDs; and discuss how primary health care models can be adapted in this context while ensuring sustainability, cost-effectiveness, and efficiency in lower and middle-income countries.

**Setting the Stage**

*D.Quick, United States; B.Chapman, United States*

**Panelist Introductions**

*D.Quick, United States*

**Why NCD? HIV and Women's Health Need Increased Attention**

*D.Quick, United States; S.Thurman, United States*

**Discussion**

**Regional, Country Experience and Young Professional Involvement in Women's HIV and NCD Issues**

*D.Lamptey, Ghana; J.Jarvis, Canada; K.Reichert, South Africa; L.Thomas Negrón, Puerto Rico*

**Discussion and Closing Remarks**

*D.Quick, United States*

**MOSA09 Key Programmatic Challenges of the Acceleration of VMMC for HIV Prevention: Cost, Demand Creation, Efficiencies and Quality of Services**

Non-Commercial Satellite

**Venue: Plenary 1**

**Date: Monday 21 July**

**Time: 18:30-20:30**

**Organizer: USAID-PEPFAR**

Policymakers and program planners who are accelerating scale up of VMMC are looking to improve efficiency, maintain or improve quality of services, create demand for services and provide timely level of supply to match existing demand, and achieve the maximum impact for the least cost. The presentations at this satellite session will highlight key findings from several countries that have moved to high volume VMMC services, explore challenges we still face, and offer recommendations for programs as they accelerate scale-up of VMMC services in their countries.

- Can health systems deliver high volume of VMMC services and still keep quality high?
  - How are program planners improving efficiency?
  - What are the key cost drivers associated with providing VMMC services?
  - What approaches have been taken to create demand for services, and what is the way forward for enhancing demand creation?
- Presenters will address these issues, among others, highlighting key findings from several countries.

**Introduction Video**

*O.Video, Afghanistan*

**Highlights from PLoS Collection: State of the VMMC Program**

*E.Njeuhmeli, United States*

## Quality of VMMC Services

*D.Rech, South Africa*

## VMMC Program Efficiencies

*W.Mavhu, Zimbabwe*

## The Potential Contribution of VMMC Programs in Addressing Low HTC and ART Enrollment Among Young Men: Lessons from Lesotho

*V.Kikaya, Lesotho*

## Questions and Answers

## VMMC and EIMC Modeling: Modeling Results on Age/Geographic Prioritization: Tanzania, Malawi, Swaziland, South Africa, Uganda, Zambia and Zimbabwe

*K.Kripke, United States*

## Demand Creation for VMMC

*K.Hatzold, Zimbabwe*

## Evidence Review: What Do We Know About the Needs of Adolescent VMMC Clients

*L.Van Lith, United States*

## Discussion

### MOSA10 The Hepatitis C Treatment Revolution: Expanding Access to HIV Co-infected and Beyond - Call to Action!

Non-Commercial Satellite

**Venue:** Melbourne Room 2

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** UNITAID - Médecins Sans Frontières (MSF) - World Health Organization (WHO)

Treatment of Hepatitis C virus (HCV) infection is radically changing with the availability of new, simpler regimens offering improved outcomes and tolerability. Without strategic market interventions, high prices disconnected from production costs will lead to significant time lag between approval and uptake by low- and middle-income countries. This session will 1) explore how low- and middle-income countries have already begun to address HCV disease; 2) describe market barriers to scale up; 3) explore how to address these barriers and; 4) consider the significant opportunities to catalyse the market to enable HCV care and treatment. In particular, speakers will focus on lessons learned during the HIV pandemic to improve access to key diagnostics and treatments, and HIV programmes as an entry point to scale up HCV diagnosis, treatment and care, especially for HIV-HCV co-infected individuals.

This session will interest country HIV programmes, donors, implementers and patient advocates.

### Global Hepatitis C Guidelines 2014: recommendations for a public health approach

*B.Waning - UNITAID, Switzerland; J.Cohn, Switzerland; G.Hirnschall - HIV Department World Health Organization, Switzerland*

### Experiencing HCV infection – the treatment, the reality and the possibilities for cure

*E.Agustain - Indonesian Drug Users Network PKNI, Indonesia*

### Hepatitis C diagnostics Technology Landscape

*M.Murtagh - UNITAID Consultant, United States*

### Overcoming IP barriers to access generic HCV medicines

*L.Menghaney - Médecins Sans Frontières Access Campaign MSF, India*

### Cost drivers for diagnosis and treatment of hepatitis C; options to contain costs

*A.Hill - Liverpool University, United Kingdom*

### Programme design to scale up HCV care in resource limited settings

*I.Andrieux-Meyer - Médecins Sans Frontières MSF, Switzerland*

### MOSA11 Science addressing drugs and HIV: State of the Art of Harm Reduction

Non-Commercial Satellite

**Venue:** Room 203-204

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** United Nations Office on Drugs and Crime (UNODC)

In March 2014, UNODC organised a scientific consultation on the State of the art on HIV and People who inject drugs, chaired by Michel Kazatchkine, UN Secretary General's Special Envoy on HIV/AIDS for EECA.

Six papers, addressing specific issues, were presented. Based on the latest scientific evidence, scientists developed and adopted a statement highlighting the current situation and barriers for accessing services, calling for harm reduction interventions, in particular NSP, OST and ART and hepatitis treatment to be scaled up and provided in a gender sensitive manner; for the closing of compulsory drug detention centres and the end of incarceration of people for minor drug related offences. This statement was presented at the High Level Segment of the 57th session of the Commission on Narcotic Drugs in March 2014. The satellite session presents the state of the art on six topics impacting HIV epidemics among people who inject drugs.

## Introduction by Co-Chairs

### Cost Effectiveness of Harm Reduction Interventions in the Context of HIV

*D.Wilson, Australia*

### Harm Reduction in the Context of HIV in Prisons

*K.Dolan, Australia*

### Women, Drugs and HIV

*T.Azim, Bangladesh*

### Prevention, Treatment and Care of Hepatitis C Among People Who Inject Drugs

*J.Grebely, Australia*

### HIV, Drugs and the Legal Environment

*S.Strathdee, United States*

### Compulsory Detention as Drug Dependence Treatment and the Impact on HIV Outcomes

*A.Kamarulzaman, Malaysia*

### Presentation of Scientific Statement

*M.Beg, UNODC*

## Discussions

### MOSA12 The Second Robert Carr Memorial Lecture: Celebrating Robert Carr's legacy

Non-Commercial Satellite

**Venue:** Clarendon Room D&E

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** ICASO, Human Rights Watch (HRW), the International AIDS Society (IAS) and the Center for Public Health and Human Rights (CPHHR) at the Johns Hopkins Bloomberg School of Public Health



Robert Carr, a tireless leader in the AIDS response worked for many years to find genuine solutions to the AIDS pandemic. In his many roles, he always advocated that comprehensive responses to AIDS must address issues of vulnerability and stigma. As a leader, Robert knew the importance of dialogue as central to building acceptance across constituencies, to revealing our fundamental similarities, and dissolving our prejudices.

At the Lecture, the Robert Carr Research Award will be presented. The Award celebrates Robert's vision of collaboration between community organizations, academic researchers and advocates to advance human rights-based policies and practices in countries where communities disproportionately affected by HIV continue to face discrimination, social rejection, violence and imprisonment, often by government officials and agencies. Robert's commitment to translating findings from research collaborations between community and academic partners into tangible policy development and advocacy efforts is the driving force behind this prize.

#### Opening Remarks

*C.Beyrer, United States; P.Jakobsson, Sweden*

#### Robert's vision of research partnerships and the role of communities

*M.Day, Saint Lucia*

#### Presentation of the Robert Carr Research Award

*M.Torres, Canada; J.Amon, United States*

#### The Second Robert Carr Memorial Lecture: Sex Work and Violence: Understanding Factors for Safety and Protection

*K.Thi Win, Myanmar*

#### Closing remarks

*M.Vallejo, Thailand*

---

#### MOSA13 Validating the Elimination of Mother-to-Child Transmission has been Achieved: Global Criteria and Current Status

Non-Commercial Satellite

**Venue:** Room 101-102

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** WHO, with UNICEF, UNAIDS and UNFPA

The Global Plan towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive was launched in 2011 and many countries in various regions are making significant progress towards global and regional targets. As a next step, countries will move towards validating EMTCT, and standardized assessment methods that apply across varying epidemiologic and programmatic contexts are necessary. To address this need, internationally standardized criteria and processes to validate EMTCT have been developed by WHO, UNICEF, UNAIDS, UNFPA and partners, and published in June 2014. Countries will receive a letter validating achievement of EMTCT when the standard criteria are met. This satellite session will present the global criteria and process to validate the elimination of mother-to-child transmission (EMTCT) of HIV and syphilis, and share experiences from regional and country processes underway to translate the criteria into action.

#### Introduction to EMTCT Validation: Criteria, Process, Tools, Current Status

*C.Hayashi, Switzerland*

#### Getting to Zero: Thailand's Experience with EMTCT

*S.Petchsri, Thailand*

#### Getting Ready for Dual EMTCT Validation in the Americas

*A.Benzaken, Brazil*

#### EMTCT Validation in the Africa Region: Regional Overview and Candidate Countries

*D.Mbori-Ngacha, UNICEF*

#### Panel Commentary by UNAIDS, UNFPA, UNICEF

*C.Luo, UNICEF; L.Loures, UNAIDS; L.Collins, UNFPA*

#### Discussion

#### Closing Remarks by WHO

*H.Nakatani, Switzerland*

---

#### MOSA14 Drug Use and HIV and HCV Infection: The Challenge and The Potential Solutions

Non-Commercial Satellite

**Venue:** Room 103

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** ANRS - NIDA

This satellite session will bring together researchers, institutional actors and community representatives to discuss the current context of prevention, harm reduction, access and barriers to treatment and therapy options for drug users. The session will also discuss HIV treatment in low and middle income countries and the implications and availability of new treatments for HCV. Finally the satellite will describe a number of specific ANRS and NIDA research projects in different regions of the world addressing some of the known gaps to improve prevention and treatment options.

#### Introduction

#### Global overview on the general context of research on HIV/HCV infection and drug use

*D.Des Jarlais, United States*

#### Treatment and access to treatment in low and middle income countries

*A.Kamarulzaman, Malaysia*

#### Global health policy and the position of international organizations and the UN (tbc)

*M.Kazatchkine, UNAIDS*

#### Discussion

*L.Ditiu, Romania*

#### Role of harm reduction in HCV prevention in France: from research to scale up

*B.Spire, France*

#### Injecting drug use and HIV - HCV infections in Dakar, Senegal: from research to implementation, the UDSEN project

*P.Girard, France*

#### Quality data and beyond - the beauty of partnership in a PWID study in Vietnam

*O.KHUAT THI HAI, Vietnam*

#### HCV among PWID In India

*S.Mehta, United States*

#### Discussion

#### Conclusions

---

#### MOSA15 Reaching young key populations: Scaling up approaches

Non-Commercial Satellite

**Venue:** Room 104

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** Interagency Working Group on Key populations and the IAS Collaborative Initiative on Paediatric HIV Education and Research (CIPHER)

This satellite session will be the official launch of the draft technical briefs on HIV and young key populations produced by the Interagency Working Group on Key Populations – making them come alive through presentations mixed with dialogues, and a panel discussion with questions from the audience. It brings together young activists, government, UN and research institutions to make a passionate call to action for creative and sustainable solutions to the development and scaling up of programmes for and with young key populations at higher risk of HIV infections.

#### Introduction to the draft technical briefs on young key populations

*P.Aguilera, Netherlands*

## The realities of young key populations: what is the evidence?

*M.Choo, Malaysia*

## A response that fits our needs: perspectives from young people from key populations: a dialogue

*H.Gercio, Philippines; B.Gurung, Nepal; V.Lieu, Vietnam*

## Tailoring services on the ground: reaching young key populations

*D.Diouf, Senegal; A.Barra, Mexico; J.Mathenge, Kenya; N.Chaiyakit, Thailand; R.Greifinger, United States*

## Legal and policy considerations in reaching young key populations

*F.Rahman, Malaysia*

## Panel discussion

*R.Baggaley, WHO; J.Butler, United States; F.Hariga, UNODC; C.Luo, UNICEF*

## Closing address

*A.Krug, Australia*

**Venue:** Room 109-110

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** AIDS Healthcare Foundation

Let's spark a renewed vision in the fight against AIDS!

What will it take to reach the next milestone in treatment access – getting 20 million people on treatment by 2020?

Testing, linkage, retention and funding are all pieces of the puzzle: join a panel of experts from AHF, WHO, UNAIDS, the Global Fund, Stop TB Partnership and others to learn how to make 20x20 a reality.

*M.Doherty, WHO*

*P.Amor, Uganda*

*W.Hao, China*

*B.Samb, Afghanistan*

*L.Ditu, Switzerland*

*A.Fakoya, Switzerland*

## MOSA16 Increasing PMTCT and Pediatric HIV/TB Treatment Coverage through Community Health Workers: Lessons and Results from using new WHO-UNICEF HIV-adapted Community Materials

Non-Commercial Satellite

**Venue:** Room 105-106

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** UNICEF and World Health Organization

Improving the health and survival of HIV-infected mothers and their children depends on women and health workers knowing the HIV/TB status of women and infants, and bringing services closer to families. Community health workers (CHW) have played a critical role in decentralizing HIV/TB care and increasing coverage of interventions. While training and support for CHWs are included as part of 'HIV investment frameworks', the actual tools and best mechanisms for supporting CHWs are less clear. In 2012, WHO and UNICEF began a process to adapt training and support materials to help CHWs interact with pregnant women in the antenatal and delivery period and for identifying sick children in the community. The session will present these adapted materials and share experiences of their use with CHWs, and preliminary results of their effectiveness.

### Co-chairs remarks: Community Health Workers and uptake of child survival and TB interventions

*D.Young, United States; D.Graham, Australia*

### 1. Opportunities and challenges for Community Health Workers to increase coverage of interventions and quality of care for HIV-exposed and infected children

*D.Rollins, Switzerland*

### 2. New WHO/UNICEF materials for CHWs - adapted to include TB and HIV-related activities and interventions (iCCM and Newborn modules)

*S.Reid, South Africa*

### 3. Quality Improvement approaches for supervising community health workers using the HIV-adapted WHO materials for CHWs: Experiences from the Nompilo study

*H.Ngidi, South Africa*

### 4. The effectiveness of a Quality Improvement intervention to supervise Community Health Workers in South Africa

*L.Butler, United States*

## Discussant

*R.Lovich, United States*

## MOSA17 20x20: Testing, Linkage, Retention and Funding – 20 Million on Treatment by 2020

Non-Commercial Satellite

## MOSA18 Creative and Novel Ideas in HIV Research: Fostering innovation and a new generation of HIV researchers

Non-Commercial Satellite

**Venue:** Room 111-112

**Date:** Monday 21 July

**Time:** 18:30-20:30

**Organizer:** U.S. National Institutes of Health (NIH), Centres for AIDS Research (CFARs) and the International AIDS Society (IAS)

The Creative and Novel Ideas in HIV Research (CNIHR) grant program is an initiative of the IAS, NIH and CFARs that is aimed at supporting research projects from early-stage scientists new to the HIV field to answer essential questions in HIV research. The purpose of the CNIHR programme is to foster a new generation of HIV researchers by providing funding, training opportunities and individualised mentoring to selected grantees.

CNIHR grantees, who have been awarded in conjunction with AIDS 2012, will present their research results during the satellite session. Their presentations will provide insights into innovative approaches and creative solutions to understand and overcome key obstacles in the HIV field ranging from HIV infections and comorbidities to research towards a cure. The session will be an inspiration for early-stage investigators and a demonstration of cutting-edge research in the HIV field.

### Opening remarks and introduction to the Creative and Novel Ideas in HIV Research Grant Programme

*S.Carrington-Lawrence, United States; A.Collier, United States*

### The biophysical underpinnings of gp120 evolvability

*J.Bloom, United States*

### Apoptotic cell clearance signalling and HIV-associated inflammation

*M.Elliott, United States*

### Cellular autophagy response on HIV infections and implications on opportunistic Mtb infections

*D.Kumar, India*

### Psoriasis and HIV-1 control

*W.Liao, United States*

### Role of FoxP3 in blocking transcriptional activation of the HIV-LTR in regulatory T cells

*R.Lowe, United States*

### Effects of adolescent stress and HIV on the stress response and neuroinflammation

*G.Neigh, United States*

**Characterization of Gag trafficking pathways in HIV-1-infected macrophages and CD4+ T cells**

*M.Ostrowski, Argentina*

**Developing small animal models of HIV elite controller and rapid progressor immunity**

*S.Sanjabi, United States*

**CCR5 mediated trafficking of HIV-infected mononuclear leukocytes at the human blood-nerve barrier in vitro**

*E.Ubogu, Nigeria*

**Closing remarks**

*S.Carrington-Lawrence, United States; A.Collier, United States*

---

**THSA13 Together with Thailand, we can end AIDS epidemics in Asia.**

Non-Commercial Satellite

**Venue: Plenary 2**

**Date: Monday 21 July**

**Time: 18:30-20:30**

**Organizer: Department of Disease Control, Ministry of Public Health, Thailand**

Objective: To discuss how to overcome key challenges of ending AIDS.

Background: Thailand's national strategy on HIV/AIDS has set targets of three zeros. National AIDS Committee endorsed additional measures based on investment framework to achieve ending AIDS by 2030.

Speakers:

1. Dr. Sophon Mekthon, D-G, Dept. of Disease Control, Thailand – Investment and changing the paradigm from controlling epidemic to ending AIDS
  2. Mr. Steve Kraus, Director, UNAIDS RST-AP – Role of UN to support countries in Asia
  3. Dr. Taweessap Siraprasiri, Director, National AIDS Management Center – From policy advocacy to program translation
  4. Prof. Dr. Kiat Ruxrungtham, Chulalongkorn University – How academic support for program implementation on life-long treatment and care
  5. Ms. Surang Janyam, Director, SWING Thailand - Role of networking of civil society on advocacy and community strengthening
  6. Mr. Omar Syarif, APN+ – International involvement and community led interventions to end AIDS in Asia
- Moderator: Dr. Sumet Ongwandee, Director, Bureau of AIDS, TB, and STIs

**Investment and changing the paradigm from controlling epidemic to ending AIDS**

*D.Mekthon, Thailand*

**Global strategies and role of UN to support countries in Asia**

*S.Krauss, United States*

**From policy advocacy to programme translation, what and how country makes it happen**

*T.Siraprasiri, Thailand*

**treatment as prevention: How academic sector support for programme implementation on life-long treatment and care**

*K.Ruxrungtham, Thailand*

**The role of networking of civil society organization on advocacy and community strengthening**

*S.Janyam, Thailand*

**International involvement and community led interventions to end AIDS in Thailand and Asia**

*O.Syarif, Indonesia*

---